Press-release for stocks

Prices are updated after-hours

market source : Www.biospace.com

save search

Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
Published: 2024-04-19 (Crawled : 13:00) - biospace.com/
ENSC | News | $0.561 -3.31% -3.42% 190K

Health Technology

| -11.72% | O: -5.53% H: 0.0% C: -6.56%
conference presentation growth

NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
NBY | $0.0824 -1.91% 0.0% 1.6M

Health Technology

| 10.96% | O: 38.7% H: 0.0% C: -20.0%
sales first revenue care pharmaceuticals for

Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
JAGX | $0.158 -10.79% -12.09% 30M

Health Technology

| 34.68% | O: 26.26% H: 73.2% C: 18.87%
health cancer care for commercial

BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule - April 11, 2024
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
BCLI A | $0.5384 4.69% 4.48% 1M

Health Technology

| -10.32% | O: -0.17% H: 13.56% C: -2.19%
nasdaq cell therapeutics market

Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1
Published: 2024-04-10 (Crawled : 13:00) - biospace.com/
GKOS | $96.5 1.44% 0.0% 700K

Health Technology

| -4.75% | O: -2.14% H: 1.92% C: 0.57%
first financial results market

Thermo Fisher Scientific Innovations at Analytica 2024 Optimize Workflows and Enable Precise Analysis Across Life Sciences, Applied and Industrial Markets
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
TMO | News | $544.78 0.6% 0.0% 1.7M

Health Technology

| -6.04% | O: 0.68% H: 0.98% C: 0.93%
life

RenovoRx Announces $11.1 Million at Market Private Placement
Published: 2024-04-08 (Crawled : 15:00) - biospace.com/
RNXT | $1.23 0.82% 0.81% 20K

| 0.0% | O: -1.71% H: 34.78% C: 1.74%
million market

Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
Published: 2024-04-04 (Crawled : 19:00) - biospace.com/
AMLX A | $1.88 -5.05% -5.32% 2.5M

| -28.9% | O: 2.28% H: 6.32% C: -2.97%
relyvrio pharmaceuticals

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
Published: 2024-04-02 (Crawled : 12:00) - biospace.com/
RDHL | $0.4519 7.39% 6.88% 330K

Health Technology

| -16.36% | O: -5.2% H: 4.9% C: 3.92%
million direct offering biopharma market

Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
Published: 2024-04-02 (Crawled : 11:00) - biospace.com/
RCKT M | $22.82 -2.81% -2.89% 960K

Health Technology

| -14.51% | O: -1.76% H: 0.0% C: -1.91%
anemia authorization treatment pharmaceuticals application

Will Oral Weight-Loss Drugs Break Open an Already Lucrative Market?
Published: 2024-04-01 (Crawled : 05:00) - biospace.com/
ARVL | News | $0.49 0.37% 2.5M

Manufacturing

| Email alert Add to watchlist

COPD Market Poised for ‘Paradigm Shift’ with Potential Approvals in 2024: Glo...
Published: 2024-03-27 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -7.26% | O: -0.26% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -5.89% | O: 1.06% H: 0.0% C: 0.0%
copd potential market

COPD Market Poised for ‘Paradigm Shift’ with Potential Approvals in 2024: GlobalData
Published: 2024-03-27 (Crawled : 12:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -7.26% | O: -0.26% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -5.89% | O: 1.06% H: 0.0% C: 0.0%
copd potential market

Tenon(R) Medical Announces Positive Fusion Results in First Patients Reaching 12-Month Follow Up in an IRB Approved, Multi-Centered, Post-Market Study Utilizing the Catamaran(R) SI Joint Fusion System
Published: 2024-03-26 (Crawled : 19:00) - biospace.com/
TNON | $0.7331 -2.25% -2.31% 31K

| -25.89% | O: 2.54% H: 1.98% C: -5.45%
first positive system medical results study

Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
Published: 2024-03-22 (Crawled : 21:00) - biospace.com/
AZZ | $74.8 -0.9% 0.0% 250K

Producer Manufacturing

| -8.85% | O: -1.74% H: 0.37% C: -3.24%
india agreement market

Avenacy Announces Launch of Furosemide for Injection in the U.S. Market
Published: 2024-03-20 (Crawled : 12:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology